A
Alpha Wave Global, LP
+ HoldingAPMD
-12.56%
3M Return
$29.710
+1.025 (+3.45%)Zum Schluss
Loading chart…
- High
- 32.370
- Open
- 29.010
- VWAP
- 30.30
- Vol
- 536.84K
- Mkt Cap
- —
- Low
- 28.830
- Amount
- 16.27M
- EV/EBITDA, TTM
- 61.01
Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
AI analysis of Apnimed Inc (APMD)
buyApnimed, Inc. is a good buy right now due to its strong recent performance, with a year-to-date change of +85.69% and a positive analyst outlook, including a target price of $60 from Cantor Fitzgerald. The upcoming FDA decision for its lead product, Oxnimbi, on February 28, 2027, adds a significant potential catalyst for growth. However, the main risk is the regulatory scrutiny associated with the FDA approval process, which could impact the stock negatively.
Bewertungskennzahlen
The current forward P/E ratio for Apnimed Inc (APMD) is 0.00, compared to its 5-year average forward P/E of .
Whales holding APMD
Event-Zeitleiste
News
6.008-25CNBCWall Street's Latest Ratings Overview
8.508-04renaissancecapitalJuly IPO Market Revives with $29.3 Billion Raised
8.508-03GlobenewswireApnimed Completes Upsized IPO Raising $220.8 Million
8.508-03NewsfilterApnimed Closes Upsized IPO Raising $220.8 Million
8.508-03renaissancecapitalRenaissance Capital's IPO Market Weekly Podcast Returns
APMD FAQ — answered by Alphio AI
Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep. It operates in the Healthcare sector.
Apnimed, Inc. is a good buy right now due to its strong recent performance, with a year-to-date change of +85.69% and a positive analyst outlook, including a target price of $60 from Cantor Fitzgerald. The upcoming FDA decision for its lead product, Oxnimbi, on February 28, 2027, adds a significant potential catalyst for growth. However, the main risk is the regulatory scrutiny associated with the FDA approval process, which could impact the stock negatively.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.